ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing

Hodgkin lymphoma (HL) resistant to conventional therapies is increasing, making of interest the search for new schemes of treatment. Members of the “A Disintegrin And Metalloproteases” (ADAMs) family, mainly ADAM10 or ADAM17, have been proposed as therapeutic targets in solid tumors and some ADAMs i...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Oncoimmunology
Autors principals: Zocchi, Maria Raffaella, Camodeca, Caterina, Nuti, Elisa, Rossello, Armando, Venè, Roberta, Tosetti, Francesca, Dapino, Irene, Costa, Delfina, Musso, Alessandra, Poggi, Alessandro
Format: Artigo
Idioma:Inglês
Publicat: Taylor & Francis 2015
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4910733/
https://ncbi.nlm.nih.gov/pubmed/27467923
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2015.1123367
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars